Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01523496 · ClinicalTrials.gov registry record · Phase 2

Vitamin D Supplementation in HIV Youth

A Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
Phase 2
Development phase
190
Enrollment target

NCT01523496: Completed Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.

NCT01523496 is a Phase 2 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 190 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01523496, a Phase 2 study, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
190 participants
Enrollment target

Study Summary

The purpose of this study is to determine the correct dose of Vitamin D to give to prevent HIV related complications.

Primary Outcome

Evaluate the dose-related efficacy of correction of Vitamin D deficiency for 25(OH)D3 levels in a group of HIV-infected children and young adults and a matched healthy control group in a randomized controlled study of different dosing regimens of oral Vitamin D supplementation: control dose (18,000 IU per month) or supplemented dose (medium 60,000IU per month or high dose 120,000IU/month )

Interventions

  • DRUG Vitamin D control dose
  • DRUG Vitamin D supplementation-

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2011-12
Est. Completion 2016-08
Phase Phase 2

What the finished NCT01523496 record still lists

NCT01523496 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher).

The record links to 0 conditions, and to 2 interventions - of which Vitamin D control dose is the first listed.

NCT01523496 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01523496 about?

NCT01523496 is a clinical study titled "Vitamin D Supplementation in HIV Youth". The purpose of this study is to determine the correct dose of Vitamin D to give to prevent HIV related complications.

What is the current status of trial NCT01523496?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2011-12. Estimated completion is 2016-08.

What interventions are being tested in trial NCT01523496?

The interventions under investigation include: Vitamin D control dose (DRUG), Vitamin D supplementation- (DRUG).

Who is sponsoring clinical trial NCT01523496?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01523496's enrollment target sits among peer trials

190 353rd of 2000 higher than 1,646 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01523496, the US trial registry maintained by the National Library of Medicine. NCT01523496 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.